NIM
CRVS icon

NEOS Investment Management’s Corvus Pharmaceuticals CRVS Stock Holding History

NEOS Investment Management’s Portfolio CRVS Stock Details CRVS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-80,893
Closed -$623K – 600
2025
Q4 		$623K Buy
80,893
+21,691
+37% +$171K ﹤0.01% 590
2025
Q3 		$436K Buy
+59,202
New +$303K ﹤0.01% 585

Other funds holding CRVS

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
ASP
Adams Street Partners Chicago, Illinois $260M AUM 30.38% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

NEOS Investment Management's CRVS Position: Q1 2026 in Review

NEOS Investment Management sold out of Corvus Pharmaceuticals (CRVS) in Q1 2026, closing a stake of 80,893 shares — an estimated $623K sold.

NEOS Investment Management first reported a position in CRVS in Q3 2025 and held it in 2 quarters. The position peaked at $623K in Q4 2025. 164 funds tracked by Wall St. Rank hold CRVS as of Q1 2026.

  • NEOS Investment Management reported no remaining Corvus Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • NEOS Investment Management sold 80,893 Corvus Pharmaceuticals shares in Q1 2026, an estimated $623K.
  • NEOS Investment Management first reported a position in Corvus Pharmaceuticals in Q3 2025 and held it in 2 quarters.
  • NEOS Investment Management's Corvus Pharmaceuticals position peaked at $623K in Q4 2025.
  • 164 funds tracked by Wall St. Rank held Corvus Pharmaceuticals as of Q1 2026.

Based on NEOS Investment Management's 13F filing for Q1 2026, filed 15 May 2026.